Answer
No. People receiving terminal-complement inhibitors remain at increased risk of invasive meningococcal disease even if antibodies develop after vaccination.
Sources for this answer
- Nimenrix powder and solvent for solution for injection in pre-filled syringe — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.